Thomas Morris

Bicalutamide 150 mg plus standard care vs standard care alone for early prostate cancer

David G. McLeod, Peter Iversen, William A. See et al. · British Journal of Urology · 2005 · 279 citations

Phase III, Randomized, Placebo-Controlled Study of Docetaxel in Combination With Zibotentan in Patients With Metastatic Castration-Resistant Prostate Cancer

Karim Fizazi, Celestia S. Higano, Joel B. Nelson et al. · Journal of Clinical Oncology · 2013 · 213 citations · Full text

Urology, Genitourinary Cancer, Medicine +14

Safety and Efficacy of the Specific Endothelin-A Receptor Antagonist ZD4054 in Patients with Hormone-Resistant Prostate Cancer and Bone Metastases Who Were Pain Free or Mildly Symptomatic: A Double-Blind, Placebo-Controlled, Randomised, Phase 2 Trial

Nicholas D. James, Armelle Caty, Michael Borre et al. · European Urology · 2008 · 160 citations

Urology, Oncology, Health Sciences +10

Antiandrogen monotherapy in patients with localized or locally advanced prostate cancer: final results from the bicalutamide Early Prostate Cancer programme at a median follow‐up of 9.7 years

Peter Iversen, David G. McLeod, William A. See et al. · British Journal of Urology · 2010 · 112 citations

Phase 3, randomized, placebo‐controlled study of zibotentan (ZD4054) in patients with castration‐resistant prostate cancer metastatic to bone

Joel B. Nelson, Karim Fizazi, Kurt Miller et al. · Cancer · 2012 · 108 citations